www.dailypolitical.com ·
Myomo Nyseamericanmyo Director Purchases 28760 55 in Stock
Topic context
This topic has been covered 245797 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedInsider purchase by a director of Myomo, a medical device company specializing in powered orthotic devices for upper-limb weakness. The transaction is small relative to market cap and does not signal a change in commercial fundamentals. No product, supply chain, or margin impact is evident. The buy rating from Craig Hallum suggests analyst optimism, but no concrete commercial mechanism is triggered.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Myomo director Thomas Kirk purchased 31,605 shares at $0.91 each on May 15, 2026.
- Total purchase value: $28,760.55.
- Kirk's ownership increased to 585,462 shares worth ~$532,770.42.
- Stock price fell to $0.84 post-transaction; market cap $32.42 million.
- Craig Hallum maintains 'buy' rating with consensus price target $7.67.